60 related articles for article (PubMed ID: 37149398)
1. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Bringhen S; Pour L; Benjamin R; Grosicki S; Min CK; C de Farias DL; Vorog A; Labotka RJ; Wang B; Cherepanov D; Cain LE; Manne S; Rajkumar SV; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):491-504. PubMed ID: 37149398
[TBL] [Abstract][Full Text] [Related]
2. Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L; Wang YT; Liu P; Lu MQ; Zhuang JL; Zhang M; Xia ZJ; Li ZL; Yang Y; Yan ZY; Jing HM; Dong F; Chen WM; Wu Y; Zhou HB; Fu R; Gong YP; Huang WR; Zhang YQ
EClinicalMedicine; 2024 Feb; 68():102431. PubMed ID: 38318126
[TBL] [Abstract][Full Text] [Related]
3.
Coulson AB; Royle KL; Pawlyn C; Cairns DA; Hockaday A; Bird J; Bowcock S; Kaiser M; de Tute R; Rabin N; Boyd K; Jones J; Parrish C; Gardner H; Meads D; Dawkins B; Olivier C; Henderson R; Best P; Owen R; Jenner M; Kishore B; Drayson M; Jackson G; Cook G
BMJ Open; 2022 Jun; 12(6):e056147. PubMed ID: 35654466
[TBL] [Abstract][Full Text] [Related]
4. More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected].
DuMontier C; La J; Bihn J; Corrigan J; Yildirim C; Dharne M; Hassan H; Yellapragada S; Abel GA; Gaziano JM; Do NV; Brophy M; Kim DH; Munshi NC; Fillmore NR; Driver JA
Blood Adv; 2023 Oct; 7(20):6275-6284. PubMed ID: 37582048
[TBL] [Abstract][Full Text] [Related]
5. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Paiva B; Manrique I; Dimopoulos MA; Gay F; Min CK; Zweegman S; Špička I; Teipel R; Mateos MV; Giuliani N; Cavo M; Hopkins CR; Fu W; Suryanarayan K; Vorog A; Li C; Wang B; Estevam J; Labotka R; Dash AB
Blood; 2023 Feb; 141(6):579-591. PubMed ID: 36130300
[TBL] [Abstract][Full Text] [Related]
6. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Tzogani K; Florez B; Markey G; Caleno M; Olimpieri OM; Melchiorri D; Hovgaard DJ; Sarac SB; Penttilä K; Lapveteläinen T; Salmonson T; Bergh J; Gisselbrecht C; Pignatti F
ESMO Open; 2019; 4(5):e000570. PubMed ID: 31555488
[TBL] [Abstract][Full Text] [Related]
7. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Richardson PG; Facon T; Venner CP; Bahlis NJ; Offner F; White D; Karlin L; Benboubker L; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Villarreal M; Twumasi-Ankrah P; Labotka R; Rifkin RM; Lonial S; Kumar SK; Rajkumar SV; Moreau P
EJHaem; 2023 Nov; 4(4):995-1005. PubMed ID: 38024593
[TBL] [Abstract][Full Text] [Related]
8. Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Ramasamy K; Bahlis NJ; Kumar SK; Kumar A; Cranmer H; Wang B; Dabora J; Labotka R; Richardson PG; Moreau P
Haematologica; 2024 Feb; ():. PubMed ID: 38426294
[TBL] [Abstract][Full Text] [Related]
9. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
Seefat MR; Stege CAM; Lissenberg-Witte BI; Levin MD; Timmers GJ; Hoogendoorn M; Ypma PF; Klein SK; Velders GA; Westerman M; Strobbe L; Durdu-Rayman N; Davidis-van Schoonhoven MA; van Kampen RJW; Dijk AC; Koster A; Silbermann MH; van der Spek E; Beeker A; Erjavec Z; de Graauw NCHP; Leys MBL; Sonneveld P; van de Donk NWCJ; Nasserinejad K; Blommestein HM; Cucchi DGJ; Zweegman S
Eur J Cancer; 2024 Jun; 207():114153. PubMed ID: 38870747
[TBL] [Abstract][Full Text] [Related]
10. Treatment of older adult or frail patients with multiple myeloma.
Grant SJ; Freeman CL; Rosko AE
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):46-54. PubMed ID: 34889397
[TBL] [Abstract][Full Text] [Related]
11. How I treat multiple myeloma in geriatric patients.
Facon T; Leleu X; Manier S
Blood; 2024 Jan; 143(3):224-232. PubMed ID: 36693134
[TBL] [Abstract][Full Text] [Related]
12. Fitness and frailty in myeloma.
Pawlyn C; Khan AM; Freeman CL
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):337-348. PubMed ID: 36485137
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).
Haider I; Leong DP; Louzada M; McCurdy A; Pond GR; Cameron R; Aljama M; Visram A; Wildes TM; Mian H
Leuk Lymphoma; 2024 Apr; ():1-8. PubMed ID: 38625039
[TBL] [Abstract][Full Text] [Related]
14. Considerations for the treatment of frail multiple myeloma patients.
Mohty M; Rajkumar SV
Clin Hematol Int; 2024; 6(1):23-25. PubMed ID: 38817702
[No Abstract] [Full Text] [Related]
15. Reply: How well can frailty predict no benefit from ICD therapy?
Gotzmann M; Lewenhardt M; Kreimer F
Clin Cardiol; 2024 Feb; 47(2):. PubMed ID: 38402554
[No Abstract] [Full Text] [Related]
16. Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study.
Srimani JK; Diderichsen PM; Hanley MJ; Labotka R; Gupta N
Clin Pharmacol Ther; 2023 Jul; 114(1):220-229. PubMed ID: 37186295
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P
Leukemia; 2023 Jul; 37(7):1521-1529. PubMed ID: 37316728
[TBL] [Abstract][Full Text] [Related]
18. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
[TBL] [Abstract][Full Text] [Related]
19. Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.
Solimando AG; Krebs M; Desantis V; Marziliano D; Caradonna IC; Morizio A; Argentiero A; Shahini E; Bittrich M
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509726
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
